Mineral

Potassium

Potassium (K⁺, as various salts: citrate, chloride, gluconate)

Evidence TierBWADA NOT PROHIBITED

tuneTypical Dose

2,600-3,400 mg/day (dietary AI). OTC supplements typically 99 mg/capsule

watchEffect Window

Weeks to months for blood pressure trends

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Potassium is an essential electrolyte for nerve signaling, muscle contraction, and cardiac rhythm. It is used to support blood pressure control and to replace losses, especially when dietary intake is low.

Higher potassium intake lowers blood pressure in intervention studies and is associated with lower stroke risk, particularly when it replaces sodium in the diet. It supports normal muscle and heart function. Minority evidence suggests reduced kidney stone risk via lower urinary calcium excretion. Excess potassium is dangerous in kidney disease or with certain medications, so benefits depend on appropriate screening.

Potassium opposes sodium's hypertensive effects via natriuresis and vasodilation, regulated through Na+/K+-ATPase pump function and vascular smooth muscle relaxation.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Dietary potassium lowers blood pressure and reduces stroke risk. OTC supplement doses (99 mg) are clinically insufficient for blood pressure goals.

Secondary Outcomes

  • Reduces urinary calcium excretion.
  • Supports neuromuscular function and fluid balance.

Safety

Contraindications and Interactions

Contraindications

  • Severe CKD (eGFR <30)
  • Existing hyperkalemia
  • Addison's disease

Side effects

  • GI upset
  • Nausea
  • Diarrhea

Interactions

  • ACE inhibitors
  • ARBs
  • Potassium-sparing diuretics (spironolactone, amiloride)
  • Cyclosporine

Avoid if

  • CKD with eGFR <30 or on dialysis
  • Potassium-sparing diuretics without lab monitoring
  • Addison's disease

Evidence

Study-level References

potassium-SRC-001Systematic review and meta-analysis
Sourceopen_in_new

Aburto NJ, et al. *Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses.* BMJ. 2013.

Population: Adults across multiple dietary and supplemental potassium trials

Dose protocol: Increased potassium intake (dietary and supplemental)

Key findings: Increased potassium intake reduces blood pressure in hypertensives and is associated with 24% lower stroke risk. No adverse effects on renal function, lipids, or catecholamines in adults without impaired renal function.

Notes: WHO used this review to inform potassium intake recommendations.

Paper content

Increased potassium intake reduces blood pressure in hypertensives and is associated with 24% lower stroke risk. No adverse effects on renal function, lipids, or catecholamines in adults without impaired renal function.

potassium-SRC-002Randomized controlled trial
Sourceopen_in_new

Appel LJ, et al. *A clinical trial of the effects of dietary patterns on blood pressure (DASH).* NEJM. 1997.

Population: Adults with and without hypertension

Dose protocol: DASH diet (potassium-rich, with fruits, vegetables, low-fat dairy)

Key findings: DASH diet significantly lowered blood pressure. Potassium-rich dietary pattern is a key contributor to the effect.

Notes: Dietary intervention, not isolated potassium supplementation. Demonstrates potassium's role within a dietary context.

Paper content

DASH diet significantly lowered blood pressure; potassium-rich dietary pattern is a key contributor to the effect.

potassium-SRC-003Regulatory
Sourceopen_in_new

FDA regulation on OTC potassium supplement dosing. 21 CFR 101.36.

Population: US dietary supplement market

Dose protocol: Caps OTC potassium at 99 mg per dosage form

Key findings: OTC potassium supplements are limited to 99 mg per dose to prevent accidental hyperkalemia, particularly in populations with impaired renal function.

Notes: Regulatory constraint that fundamentally limits OTC supplement efficacy for blood pressure goals.

Paper content

OTC potassium supplements are limited to 99 mg per dose to prevent accidental hyperkalemia, particularly in populations with impaired renal function.

potassium-SRC-004Dose-response meta-analysis of randomized controlled trials.
Sourceopen_in_new

Filippini T, Naska A, Kasdagli MI, Torres D, Lopes C, Carvalho C, Moreira P, Malavolti M, Orsini N, Whelton PK, Vinceti M. Potassium intake and blood pressure: a dose-response meta-analysis of randomized controlled trials. J Am Heart Assoc. 2020;9(12):e015719. doi:10.1161/JAHA.119.015719. PMID:32500831.

Population: Adults from 32 randomized controlled trials, mostly with hypertension.

Dose protocol: Meta-analysis of 32 RCTs with potassium supplementation 30-140 mmol/day.

Key findings: U-shaped dose-response curve. BP reduction strongest up to about 30 mmol/day increase, with diminishing returns and possible adverse effects above 80 mmol/day.

Notes: Important for dose-safety messaging. Supports adequate but not excessive potassium intake.

Paper content

This dose-response meta-analysis of 32 RCTs modeled the relationship between potassium supplementation and blood pressure using cubic spline regression. The analysis found a U-shaped curve where BP reduction was strongest at moderate potassium increases (up to about 30 mmol/day), with weakening benefit above that threshold and a concerning BP increase above approximately 80 mmol/day. The effect was most pronounced in hypertensive participants with elevated sodium intake. Notably, drug-treated hypertensive individuals showed potential adverse effects at high potassium doses. The findings support adequate potassium intake for BP management but caution against excessive supplementation.

potassium-SRC-005Dose-response meta-analysis of randomized clinical trials.
Sourceopen_in_new

Granal M, Sourd V, Burnier M, Fauvel JP, Gougeon A. Effect of changes in potassium intake on blood pressure: a dose-response meta-analysis of randomized clinical trials (2000-2024). Clin Kidney J. 2025;18(7):sfaf173. doi:10.1093/ckj/sfaf173. PMID:40612568.

Population: Adults from 10 RCTs published 2000-2024, including normotensive and hypertensive subjects.

Dose protocol: Meta-analysis of 10 RCTs (2000-2024) with urinary potassium as exposure metric.

Key findings: In hypertensive subjects, 50 mmol/day potassium increase reduced SBP by 5.3 mmHg and DBP by 3.62 mmHg. In normotensive subjects, only 0.5 mmHg SBP reduction.

Notes: Small trial count but reinforces that potassium benefit is concentrated in hypertensive populations.

Paper content

This 2025 dose-response meta-analysis pooled 10 RCTs published from 2000 to 2024 to quantify the effect of potassium intake changes on blood pressure. The key finding was a large differential effect by baseline blood pressure status. In hypertensive subjects, a 50 mmol/day increase in urinary potassium was associated with a 5.3 mmHg reduction in systolic BP and 3.62 mmHg reduction in diastolic BP. In normotensive subjects, the same increase produced only a 0.5 mmHg systolic reduction and minimal diastolic change. The findings reinforce that potassium's blood pressure benefit is concentrated in people with hypertension, which has practical implications for supplement targeting. The small number of included trials limits precision.

Guides

Setup

Help